According to ASCO guidelines, patients with EC should undergo comprehensive biomarker assessments, including HER2, PD‐L1, dMMR/MSI‐H, NTRK, BRAF, RET, and tumor mutational burden (TMB) testing. The gene discussed is BRAF; the disease is neoplasm.